UniProt O75385 · PDB · AlphaFold · Substrate: MBP · Clone: aa 1-649
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Brigatinib | 92.8% | 7.2% | 82.96 | 0.513 |
| 2 | Sunitinib | 72.4% | 27.6% | 91.73 | 0.524 |
| 3 | Ceritinib | 69.8% | 30.2% | 95.44 | 0.618 |
| 4 | Axitinib | 65.7% | 34.3% | 93.23 | 0.688 |
| 5 | Dabrafenib | 61.0% | 39.0% | 94.74 | 0.633 |
| 6 | Defactinib | 58.8% | 41.2% | 92.68 | 0.450 |
| 7 | Fostamatinib | 58.6% | 41.4% | 96.74 | 0.613 |
| 8 | Baricitinib | 54.8% | 45.2% | 97.99 | 0.616 |
| 9 | Bosutinib | 45.7% | 54.3% | 87.22 | 0.555 |
| 10 | Fedratinib | 38.5% | 61.5% | 96.21 | 0.576 |
| 11 | Ruxolitinib | 36.7% | 63.3% | 98.25 | 0.592 |
| 12 | Selpercatinib | 35.3% | 64.7% | 96.72 | 0.635 |
| 13 | Crizotinib | 30.9% | 69.1% | 91.39 | 0.581 |
| 14 | Abemaciclib | 28.1% | 71.9% | 91.48 | 0.563 |
| 15 | Palbociclib | 25.2% | 74.8% | 98.75 | 0.673 |
| 16 | Repotrectinib | 21.7% | 78.3% | 84.21 | 0.608 |
| 17 | Tivozanib | 18.8% | 81.2% | 92.42 | 0.673 |
| 18 | Abrocitinib | 17.6% | 82.4% | 99.50 | 0.581 |
| 19 | Dasatinib | 15.2% | 84.8% | 87.97 | 0.699 |
| 20 | Neratinib | 14.0% | 86.0% | 93.18 | 0.597 |
Paralog block
ULK1, ULK2, ULK3
EMT expression
- Mesenchymal log2(TPM+1): 3.59
- Epithelial log2(TPM+1): 3.79
- Fold change: -0.21
- Status: No significant change
Selectivity landscape vs inhibition on ULK1
Each point is one of the 92 approved drugs; color = inhibition % on ULK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…